Overactive Bladder Treatment Market

The Overactive Bladder Treatment market is expected to grow from USD 4.08 billion in 2019 to USD 5.04 billion by 2025 at a CAGR of 3.07% from 2020 to 2026.

Overactive bladder could be a medical syndrome, outlined by urinary incontinence typically characterised by high urine frequency or nocturia. The common symptoms of OAB includes urgency, high urinary frequency and urge incontinence. Anticholinergic agents are thought-about because the initial line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are a number of the generic drugs used for the treatment of overactive bladder. These medicine acts by antagonizing cholinergic receptors that has the relief from the frequent urination.

The global Overactive Bladder Treatment market is segregated on the basis of Therapy Type as Anticholinergics, Solifenacin, Oxybutynin, Darifenacin, Fesoterodine, Tolterodine, Trospium, Other Anticholinergics*, Mirabegron, and BOTOX. Based on Disease the global Overactive Bladder Treatment market is segmented in Idiopathic Bladder Overactivity and Neurogenic Bladder Overactivity.

The global Overactive Bladder Treatment market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Overactive Bladder Treatment market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Competitive Rivalry

Astellas Pharma Inc. , Pfizer, Inc.  , Teva Pharmaceutical Industries Limited  , Allergan, PLC.  , Mylan N.V.  , Endo International PLC  , Hisamitsu Pharmaceutical Co., Inc. , Sanofi , Aurobindo Pharma Limited  , Johnson & Johnson , and others are among the major players in the global Overactive Bladder Treatment market. The companies studied in terms of product strategy and various n several growth and expansion strategies to gain a competitive edge in the market. The major players not only follow value chain integration with business operations in multiple stages of the value chain.

The global Overactive Bladder Treatment market has been segmented as below:

Overactive Bladder Treatment Market, By Therapy Type

• Anticholinergics
• Solifenacin
• Oxybutynin
• Darifenacin
• Fesoterodine
• Tolterodine
• Trospium
• Other Anticholinergics*
• Mirabegron
• BOTOX
• Neurostimulation

Overactive Bladder Treatment Market, By Disease

• Idiopathic Bladder Overactivity
• Neurogenic Bladder Overactivity

Overactive Bladder Treatment Market, By Region

• North America
• Europe
• Asia-Pacific
• Rest of the World

Overactive Bladder Treatment Market, By Company

• Astellas Pharma Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Limited
• Allergan, PLC.
• Mylan N.V.
• Endo International PLC
• Hisamitsu Pharmaceutical Co., Inc.
• Sanofi
• Aurobindo Pharma Limited
• Johnson & Johnson
• Intas Pharmaceuticals Ltd.
• Apotex Inc.
• Macleods Pharmaceuticals Ltd.
• Medtronic PLC

The report covers the below scope:

• Global Overactive Bladder Treatment market sizes from 2015 to 2024, along with CAGR for 2018-2024
• Market size comparison for 2017 vs 2024, with actual data for 2017, estimates for 2018 and forecast from 2019 to 2024
• Global Overactive Bladder Treatment market trends, covering comprehensive range of consumer trends & manufacturer trends
• Value chain analysis covering participants from raw material suppliers to the downstream buyer in the global Overactive Bladder Treatment market
• Major market opportunities and challenges in forecast timeframe to be focused
• Competitive landscape with analysis on competition pattern, portfolio comparisons, development trends and strategic management
• Comprehensive company profiles of the key industry players

The years considered for the study are as follows:

• Base year - 2018
• Estimated year - 2019
• Projected year - 2020
• Forecast period - 2021 to 2025

Report Scope:

The global Overactive Bladder Treatment market report scope includes detailed study covering underlying factors influencing the industry trends. The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies. The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Overactive Bladder Treatment market share. Major industry players with significant revenue share include Astellas Pharma Inc. , Pfizer, Inc.  , Teva Pharmaceutical Industries Limited  , Allergan, PLC.  , Mylan N.V.  , Endo International PLC  , Hisamitsu Pharmaceutical Co., Inc. , Sanofi , Aurobindo Pharma Limited  , Johnson & Johnson , and others.

Why to Buy this Report:

• Gain detailed insights on the Overactive Bladder Treatment industry trends
• Find complete analysis on the market status
• Identify the Overactive Bladder Treatment market opportunities and growth segments
• Analyse competitive dynamics by evaluating business segments & product portfolios
• Facilitate strategy planning and industry dynamics to enhance decision making

Target Audience:

The report targeted towards the existing players in the industry is as follows:

• Market Manufacturers/Service Providers
• Market Wholesale/Traders
• Investment and Financial Institutions

Free and Paid Customization based on the requirement

Report Content

 

1. Introduction

            1.1 Key Insights

            1.2 Report Overview

            1.3 Markets Covered

            1.4 Stakeholders

2. Research Methodology

            2.1 Research Scope

            2.2 Market Research Process

            2.3 Research Data Analysis

                        2.4.1 Secondary Research

                        2.4.2 Primary Research

                        2.4.3 Models for Estimation

            2.5 Market Size Estimation

                        2.5.1 Bottom-Up Approach - Segmental Market Analysis

                        2.5.2 Top-Down Approach - Parent Market Analysis

3. Executive Summary
4. Market Overview

            4.1 Introduction

                        4.2.1 Drivers

                        4.2.2 Restraints

                        4.2.3 Opportunities

                        4.2.4 Challenges

            4.2 Porter''s Five Force Analysis

5. Overactive Bladder Treatment Market, By Therapy Type

            5.1 Introduction

            5.2 Anticholinergics

                        5.2.1 Market Overview

                        5.2.2 Market Size and Forecast

            5.3 Solifenacin

                        5.3.1 Market Overview

                        5.3.2 Market Size and Forecast

            5.4 Oxybutynin

                        5.4.1 Market Overview

                        5.4.2 Market Size and Forecast

            5.5 Darifenacin

                        5.5.1 Market Overview

                        5.5.2 Market Size and Forecast

            5.6 Fesoterodine

                        5.6.1 Market Overview

                        5.6.2 Market Size and Forecast

            5.7 Tolterodine

                        5.7.1 Market Overview

                        5.7.2 Market Size and Forecast

            5.8 Trospium

                        5.8.1 Market Overview

                        5.8.2 Market Size and Forecast

            5.9 Other Anticholinergics*

                        5.9.1 Market Overview

                        5.9.2 Market Size and Forecast

            5.10 Mirabegron

                        5.10.1 Market Overview

                        5.10.2 Market Size and Forecast

            5.11 BOTOX

                        5.11.1 Market Overview

                        5.11.2 Market Size and Forecast

6. Overactive Bladder Treatment Market, By Disease

            6.1 Introduction

            6.2 Idiopathic Bladder Overactivity

                        6.2.1 Market Overview

                        6.2.2 Market Size and Forecast

            6.3 Neurogenic Bladder Overactivity

                        6.3.1 Market Overview

                        6.3.2 Market Size and Forecast

7. Overactive Bladder Treatment Market, By Geography

            7.1 Introduction

            7.2 North America

                        7.2.1 North America Overactive Bladder Treatment, By Therapy Type

                        7.2.2 North America Overactive Bladder Treatment, By Disease

            7.3 Europe

                        7.3.1 Europe Overactive Bladder Treatment, By Therapy Type

                        7.3.2 Europe Overactive Bladder Treatment, By Disease

            7.4 Asia-Pacific

                        7.4.1 Asia-Pacific Overactive Bladder Treatment, By Therapy Type

                        7.4.2 Asia-Pacific Overactive Bladder Treatment, By Disease

            7.5 Rest of the World

                        7.5.1 Rest of the World Overactive Bladder Treatment, By Therapy Type

                        7.5.2 Rest of the World Overactive Bladder Treatment, By Disease

8. Competitive Insights

            8.1 Key Insights

            8.2 Company Market Share Analysis

            8.3 Strategic Outlook

                        8.3.1 Mergers & Acquisitions

                        8.3.2 New Product Development

                        8.3.3 Portfolio/Production Capacity Expansions

                        8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements

                        8.3.5 Others

9. Company Profiles

• Astellas Pharma Inc.
• Pfizer, Inc.
• Teva Pharmaceutical Industries Limited
• Allergan, PLC.
• Mylan N.V.
• Endo International PLC
• Hisamitsu Pharmaceutical Co., Inc.
• Sanofi
• Aurobindo Pharma Limited
• Johnson & Johnson
• Intas Pharmaceuticals Ltd.
• Apotex Inc.
• Macleods Pharmaceuticals Ltd.
• Medtronic PLC